Transaction overview
eVisit, a portfolio company of Goldman Sachs Asset Management, acquired Bluestream Health on April 27, 2023. The acquisition aims to enhance eVisit's digital front door capabilities and integrate language services for patients seeking care access. While the financial details were not disclosed, this move solidifies eVisit’s position in the expanding virtual health sector.
Deal structure and financing
The exact equity and debt composition of the deal remains undisclosed. Mufson Howe Hunter served as the exclusive financial advisor to Bluestream Health during the transaction. No information was provided regarding any seller's retained stake or lock-up terms for key stakeholders post-acquisition. Additionally, there is no mention of IPO optionality for either party following this acquisition.
Strategic context
eVisit's rationale for acquiring Bluestream Health revolves around expanding its digital front door offerings and incorporating advanced language services to enhance patient care access. By integrating Bluestream’s tools and workflow systems, eVisit aims to provide a more comprehensive solution that streamlines patient navigation and clinician management. This acquisition supports eVisit's goal of improving operational efficiency for healthcare providers while ensuring better outcomes and financial stability.
Bluestream Health, on the other hand, divested its assets to Mufson Howe Hunter’s client with the potential backing from Goldman Sachs Asset Management. The sale likely reflects a strategic decision by Bluestream Health to align with an acquirer that can further develop and scale their digital health platform. The valuation of this transaction is not disclosed, making it challenging to compare against recent deals in the sector.
Regulatory path
Given the nature of the deal within the U.S. healthcare technology market, both the Federal Trade Commission (FTC) and Department of Justice (DOJ) could have been involved in reviewing the transaction for antitrust concerns. However, no specific regulatory hurdles or remedies are mentioned. The lack of disclosure regarding filing dates with HSR or EU competition authorities suggests that any required filings might be under review or completed without public notice.
Without detailed information on the timing and outcomes of regulatory reviews, it is unclear if there were any significant delays due to antitrust scrutiny. Nonetheless, given eVisit’s backing from Goldman Sachs Asset Management and its strategic expansion into digital front door solutions, the deal likely received expedited approval in jurisdictions relevant to healthcare technology acquisitions.